ATE324898T1 - Behandlung von hiv infektionen - Google Patents
Behandlung von hiv infektionenInfo
- Publication number
- ATE324898T1 ATE324898T1 AT99906918T AT99906918T ATE324898T1 AT E324898 T1 ATE324898 T1 AT E324898T1 AT 99906918 T AT99906918 T AT 99906918T AT 99906918 T AT99906918 T AT 99906918T AT E324898 T1 ATE324898 T1 AT E324898T1
- Authority
- AT
- Austria
- Prior art keywords
- cytostatic
- cytotoxic
- respect
- cells
- disclosed
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/032,881 US6800616B2 (en) | 1998-02-26 | 1998-02-26 | Treatment of HIV infections |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE324898T1 true ATE324898T1 (de) | 2006-06-15 |
Family
ID=21867353
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99906918T ATE324898T1 (de) | 1998-02-26 | 1999-02-11 | Behandlung von hiv infektionen |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US6800616B2 (de) |
| EP (1) | EP1056459B1 (de) |
| AT (1) | ATE324898T1 (de) |
| CA (1) | CA2320764A1 (de) |
| DE (1) | DE69931148D1 (de) |
| WO (1) | WO1999043328A1 (de) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2337565A1 (en) * | 2000-02-25 | 2001-08-25 | Cordis Corporation | Use of cladribine on a stent to prevent restenosis |
| US20030065382A1 (en) * | 2001-10-02 | 2003-04-03 | Fischell Robert E. | Means and method for the treatment of coronary artery obstructions |
| US20050260136A1 (en) * | 2004-05-20 | 2005-11-24 | Kaplan Leonard L | Topical immune competency diagnostic compositions and methods of use |
| BR112023003432A2 (pt) | 2020-09-10 | 2023-03-21 | Merck Patent Gmbh | Regime de tratamento para o tratamento de doenças autoimunes |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5087618A (en) | 1982-05-18 | 1992-02-11 | University Of Florida | Redox carriers for brain-specific drug delivery |
| US4565696A (en) | 1983-08-03 | 1986-01-21 | The Regents Of The University Of California | Production of immunogens by antigen conjugation to liposomes |
| US4713372A (en) | 1984-03-16 | 1987-12-15 | Warner-Lambert Company | 2-chloropentostatin compound having adenosine diaminase inhibitory activity |
| US5700785A (en) | 1984-07-11 | 1997-12-23 | Temple University - Of The Commonwealth System Of Higher Education | 3'-deoxy or 3'-O-substituted-2',5'-oligoadenylates as antiviral agents |
| US4912092A (en) | 1986-03-27 | 1990-03-27 | The Regents Of The University Of California | Methods for increasing extracellular adenosine and for stabilizing mast cells |
| US4871817A (en) | 1986-12-31 | 1989-10-03 | General Electric Company | Polyetherimide-liquid crystal polymer blends |
| US5459256A (en) | 1987-04-17 | 1995-10-17 | The Government Of The United States Of America As Represented By The Department Of Health And Human Services | Lipophilic, aminohydrolase-activated prodrugs |
| US5521162A (en) | 1987-08-26 | 1996-05-28 | Merrell Pharmaceuticals Inc. | Aristeromycin analogues of 4',5'-didehydro-5'-fluoro-adenosine and methods of treating neoplastic and viral disease conditions |
| US4997818A (en) | 1987-09-21 | 1991-03-05 | The University Hospital | Therapeutic method for selectively treating terminal deoxynucleotidyl transferase-positive neoplastic leukemias and lymphomas |
| US5017566A (en) | 1987-12-30 | 1991-05-21 | University Of Florida | Redox systems for brain-targeted drug delivery |
| US5292725A (en) | 1988-08-25 | 1994-03-08 | Prendergast Patrick T | Administering particular compounds against various parasites, mycoplasmas, other indications and other infections |
| IE882585L (en) | 1988-08-25 | 1990-02-25 | Prendergast Patrick T | Viral treatment system |
| US5411947A (en) | 1989-06-28 | 1995-05-02 | Vestar, Inc. | Method of converting a drug to an orally available form by covalently bonding a lipid to the drug |
| US5026687A (en) * | 1990-01-03 | 1991-06-25 | The United States Of America As Represented By The Department Of Health And Human Services | Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds |
| US5250529A (en) | 1990-02-08 | 1993-10-05 | Kos Pharmaceuticals, Inc. | Method alleviating migraine headache with mast cell degranulation blocking agents |
| US5177064A (en) | 1990-07-13 | 1993-01-05 | University Of Florida | Targeted drug delivery via phosphonate derivatives |
| US5561136A (en) | 1990-12-13 | 1996-10-01 | Merrell Pharmaceuticals Inc. | Method of treating cancer by conjunctive therapy with N,N'-bis[ethylamino)propyl]-1,7-heptanediamine and a cytotoxic agent |
| JPH04334377A (ja) | 1990-12-31 | 1992-11-20 | Akzo Nv | 酸−不安定性リンカー分子 |
| US5409690A (en) | 1993-06-23 | 1995-04-25 | Chemex Pharmaceuticals, Inc. | Treatment of multidrug resistant diseases in cancer cell by potentiating with masoprocol |
| US5366960A (en) | 1993-08-26 | 1994-11-22 | Warner-Lambert Company | Method of treating cerebral and cardiovascular disorders employing [R]3-(2-deoxy-β-D-erythro-pentofuranosyl)-3,6,7,8-tetrahydroimidaz 0-[4,5-d][1,3]diazepin-8-ol |
| US5843912A (en) * | 1994-07-06 | 1998-12-01 | Universy Of Maryland | Ring-expanded nucleosides and nucleotides |
| US5663155A (en) | 1994-11-30 | 1997-09-02 | The University Hospital | Compositions for the treatment of parasitic infections |
| US5679648A (en) | 1994-11-30 | 1997-10-21 | The University Hospital | Methods for the treatment and prevention of fungal infections by administration of 3'-deoxypurine nucleosides |
| US5659023A (en) | 1995-02-01 | 1997-08-19 | Gilead Sciences, Inc. | Nucleotide analogues |
| US6277830B1 (en) * | 1998-10-16 | 2001-08-21 | Schering Corporation | 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon |
-
1998
- 1998-02-26 US US09/032,881 patent/US6800616B2/en not_active Expired - Fee Related
-
1999
- 1999-02-11 DE DE69931148T patent/DE69931148D1/de not_active Expired - Lifetime
- 1999-02-11 WO PCT/US1999/002955 patent/WO1999043328A1/en not_active Ceased
- 1999-02-11 EP EP99906918A patent/EP1056459B1/de not_active Expired - Lifetime
- 1999-02-11 AT AT99906918T patent/ATE324898T1/de not_active IP Right Cessation
- 1999-02-11 CA CA002320764A patent/CA2320764A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DE69931148D1 (de) | 2006-06-08 |
| EP1056459B1 (de) | 2006-05-03 |
| CA2320764A1 (en) | 1999-09-02 |
| WO1999043328A1 (en) | 1999-09-02 |
| EP1056459A1 (de) | 2000-12-06 |
| US20010049359A1 (en) | 2001-12-06 |
| US6800616B2 (en) | 2004-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA200600076A1 (ru) | Композиции и способы увеличения активности теломеразы | |
| PT730465E (pt) | Utilizacao de angiotensina iii e de analogos desta em cicatrizacao de tecidos | |
| DE69030880D1 (de) | Zusammensetzung zur Stimulierung des Immunsystems | |
| BG100455A (en) | Hiv protease inhibitors | |
| Malley et al. | Synergistic anti-human immunodeficiency virus type 1 effect of hydroxamate compounds with 2', 3'-dideoxyinosine in infected resting human lymphocytes. | |
| DE69932183D1 (de) | ANWENDUNG VON ZIELGERICHTETEM RADIUM 223 FüR PALLIATIVE UND THERAPEUTISCHE BEHANDLUNG VON KNOCHENKREBS | |
| ATE319427T1 (de) | Zusammensetzungen zur anwendung von entzündungshemmenden, insbesondere antiseptischen und/oder wundheilenden wirkstoffen im oberen atemwegtrakt und/oder ohr | |
| BRPI0413574A (pt) | aplicação de polipeptìdeos da famìlia cupredoxina na terapia do cáncer | |
| UA35567C2 (uk) | Фармацевтичний препарат для лікування хворих з порушеннями функції коагуляції, спосіб лікування таких хворих, спосіб одержання фармацевтичного препарату | |
| ATE277628T1 (de) | Behandlung von hematopoietischen zellen mit cxcr4 agonisten | |
| DE69518840D1 (en) | N-(3-amino-2-hydroxybutyl)sulfonamid-derivate as hiv-protease-inhibitoren | |
| ATE385807T1 (de) | Pharmazeutische verbindung und methoden zur behandlung von menschlichen karzinomen mittels arginin entzug | |
| ATE426402T1 (de) | Medizinische zusammensetzungen enthaltend 2-amino-2-a2-(4-octylphenyl)ethylupropan-1,3-di l | |
| EA199700241A1 (ru) | Новые, определенные по составу смеси ферментов для выделения клеток и лечения ран | |
| ATE230609T1 (de) | Verfahren zur behandlung von entzündungen und zusammensetzungen dafür | |
| ES2132383T3 (es) | Inhibidores de proteasa hiv. | |
| DE69909747D1 (de) | Pharmazeutische zusammensetzung, enthaltend peg-asparaginase, für die behandlung von hiv infektionen | |
| BR0311371A (pt) | Composições para uso terapêutico compreendendo uma vitamina, um sal de metal e insulina ou um hormÈnio de crescimento | |
| DE69931148D1 (de) | Behandlung von hiv infektionen | |
| ATE395064T1 (de) | Kombinationspräparate von 3-n- formylhydroxylaminopropylphosphonsäurederivaten oder 3-n- acetylhydroxylaminopropylphosphonsäurederivaten mit speziellen pharmazeutischen wirkstoffen | |
| UY26514A1 (es) | " composición para el tratamiento de tejidos danados". | |
| FR2358893A1 (fr) | Composition antimicrobienne contenant des 1-imidazolyl-butane-2-ones ou -butane-2-ols halogenes | |
| BR9913846A (pt) | Antagonista receptor de quemocina e ciclosporina em terapia combinada | |
| NO20022109D0 (no) | Anvendelse av treosulfan for behandling av pasienter för benmargs- eller blodstamcelletansplantasjon | |
| DE69734349D1 (de) | Behandlung von knochenleiden mit adrenomedullin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |